[Therapy of obesity with liraglutide. NN8022-1807 study].
Scherbaum
W A
WA
Klinik für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany. Scherbaum@uni-duesseldorf.de
Nitschmann
S
S
D000284:Administration, Oral; D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004038:Diet, Reducing; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D007783:Lactones; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077403:Orlistat